in vivo News and Research

RSS

Researchers identify new behavior for the human macrophage

Researchers at the Institute of Human Virology of the University of Maryland School of Medicine have identified a new behavior for the human macrophage that provides new explanations for several features of HIV biology, including how the virus persists within the body indefinitely, how quiescently infected CD4+ T-cells arise, and how the infection leads to depletion of CD4+ T-cells.

19 Jul 2012

Super-resolution microscopy highlights bacterial biofilms

A multi-fluorescent labeling strategy combined with super-resolution light microscopy has allowed researchers to observe the development of a bacterial biofilm in realtime.

18 Jul 2012

GE Healthcare announces final results from [18F]flutemetamol phase 3 study on AD

GE Healthcare today announced the final results from a phase 3 study of the investigational PET amyloid imaging agent, [18F]flutemetamol in terminally ill patients who had agreed to undergo postmortem brain autopsy.

18 Jul 2012

PsychoGenics, Afraxis partner to offer Enhanced Spine Platform technology

Afraxis and PsychoGenics today announced an alliance to offer Afraxis' Enhanced Spine Platform (ESP) technology as part of PsychoGenics' comprehensive testing capabilities and drug discovery services.

17 Jul 2012

New paper documents discovery of novel lipids, including MC3

Alnylam Pharmaceuticals, a leading RNAi therapeutics company, and collaborators announced today the publication of a scientific paper documenting the discovery of novel lipids used in second generation lipid nanoparticles (LNPs) for systemic delivery of RNAi therapeutics.

14 Jul 2012

AOSSM to present ten research awards and seven grants during annual meeting in Baltimore

In order to recognize and encourage cutting-edge research in key areas of orthopaedic sports medicine, the American Orthopaedic Society for Sports Medicine (AOSSM) will present ten research awards and seven grants during its Annual Meeting, July 12-15 in Baltimore, MD. As a leader in orthopaedic sports medicine, AOSSM annually provides more than $350,000 to research initiatives and projects around the country.

12 Jul 2012

Physiologists, neuropathologists identify origin of cancer metastasis formation

It is not primary tumors that are responsible for the majority of cancer deaths, but rather their metastases. Physiologists and neuropathologists from the University of Zurich have now identified the origin of metastasis formation, thereby becoming the first to reveal the pathway of metastasizing intestinal cancer cells out of the blood stream. The results allow new approaches in the development of cancer therapies.

12 Jul 2012

Cylene's Pol I inhibitor activates p53 and selectively destroys cancer cells

Cylene Pharmaceuticals today announced that research collaborators at the Peter MacCallum Cancer Centre (Peter Mac) in Melbourne, Australia have established, for the first time, that RNA Polymerase I (Pol I) activity is essential for cancer cell survival and that its inhibition selectively activates p53 to kill tumors. Published today in Cancer Cell, the findings show that Cylene's Pol I inhibitor, CX-5461, selectively destroys cancer by activating p53 in malignant but not in normal cells.

11 Jul 2012

Read-through molecule improves muscle function in DMD

A compound that results in a read-through on nonsense mutations in messenger RNA restores dystrophin expression in an animal model of Duchenne muscular dystrophy, research shows.

9 Jul 2012

Next generation predictive 3D cell toxicity assays to be developed by Medicyte GmbH and Reinnervate Ltd

Two market leading companies in the field of cell based assays and predictive toxicology today announced a new product collaboration. Medicyte (inventors of the upcyte® technology) and Reinnervate (market leaders in the growing field of 3D cell culture) said they will work together to combine their upcyte® and Alvetex®Scaffold technologies to bring next generation cell bases assays to the biopharma and academic research markets.

9 Jul 2012

Bioengineers develop microfluidic platform to mechanically confine cancer cells

It's well known in conventional biology that during the process of mammalian cell division, or mitosis, a mother cell divides equally into two daughter cells. But when it comes to cancer, say UCLA researchers, mother cells may be far more prolific.

6 Jul 2012

Researchers to use nanoscopic clay for controlled release of drugs in patients

University of Granada and the Spanish Consejo Superior de Investigaciones Cient-ficas (CSIC) researchers will use nanoscopic clay for the controlled release of drugs in patients, with the aim of designing more efficient and less toxic drugs. This is a pilot research study that includes CSIC and University of Granada researchers and researchers from other institutions.

6 Jul 2012

Insight into understanding IDH mediated disease

Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in cancer metabolism, announced today the publication of a new study that provides further evidence of the link between a mutated metabolic enzyme and acute myeloid leukemia (AML), one of the most common types of leukemia in adults.

6 Jul 2012

Treating Sickle Cell Disease with L-Glutamine

By focusing on how best to help patients, researchers can sometimes find solutions that are much simpler than anticipated. That has been the guiding approach to our efforts to develop a treatment for sickle cell disease.

3 Jul 2012

Quality solutions for inhaler testing: new edition published by Copley

The new version of ‘Quality Solutions for Inhaler Testing’ from Copley Scientific not only showcases the latest developments in inhaled product testing equipment but also provides practical guidance on achieving robust and reliable measurement and analysis.

3 Jul 2012

Scientists discover Eya1 enzyme control of pulmonary barrier integrity

Scientists have provided the first evidence that an enzyme called Eya1 protein phosphatase is a critical regulator of lung function and that this may have broad implications for sufferers of a variety of pulmonary diseases.

3 Jul 2012

Researchers identify genes that influence degeneration of the hippocampus

In a genome-wide association (GWA) study, researchers from Boston University Schools of Medicine (BUSM) and Public Health (BUSPH) have identified several genes which influence degeneration of the hippocampus, the part of the brain most associated with Alzheimer disease (AD).

29 Jun 2012

Magnet guides iron-loaded cells to specific damaged sites in the heart

Optimal stem cell therapy delivery to damaged areas of the heart after myocardial infarction has been hampered by inefficient homing of cells to the damaged site. However, using rat models, researchers in France have used a magnet to guide cells loaded with iron oxide nanoparticles to key sites, enhancing the myocardial retention of intravascularly delivered endothelial progenitor cells.

27 Jun 2012

RXi Pharmaceuticals initiates RXI-109 Phase 1 trial to reduce surgical scars

RXi Pharmaceuticals Corporation today announced that it successfully initiated its first ever clinical study with an RNAi compound, RXI-109, using their proprietary self-delivering RNAi technology.

27 Jun 2012

Nanoparticles that can slip through mucus barriers shown to protect against herpes infections

Johns Hopkins researchers say they have demonstrated, for the first time in animals, that nanoparticles can slip through mucus to deliver drugs directly to tissue surfaces in need of protection. The researchers used these mucus-penetrating particles (MPPs) to protect against vaginal herpes infections in mice and the goal is to create similar MPPs to deliver drugs that protect humans against sexually transmitted diseases or even treat cancer.

26 Jun 2012